This podcast aims to bring you a daily summary of the most relevant news in Pharma and BioTech. Check our website at: https://www.buzzsprout.com/2189790
…
continue reading
Pharma And BioTech News Podcasts
Pharmaceutical and biotech news in 5 minutes. Drug approvals, clinical trials, and healthcare innovation.
…
continue reading
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
…
continue reading
Welcome to The Pharma Podcast - Insights from industry experts and business leaders about important and current topics in Canadian Pharma, Biotech and Medtech.
…
continue reading
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more!
…
continue reading
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
…
continue reading
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimer https://biobizbuzz.com/disclaimer/
…
continue reading
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
…
continue reading
News and Analysis of the Biotech and Pharma Industry for Investors and Executives.
…
continue reading
A weekly audio digest of the most important news in drug development affecting the pharmaceutical and biotech industry
…
continue reading
This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.
…
continue reading
The impact of modern medicine on the human condition can’t be underestimated. From antibiotics to vaccines, medicine has changed the way our bodies work, answered deadly questions, and promised faster cures. But it’s not simple. Drug development is rife with tension. It costs a lot of money, and takes a long time. Most things fail. But when they succeed, they can make a tremendous difference in people’s lives. Where will the next breakthroughs come from? How will we pay for them? Who decides ...
…
continue reading
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of pe ...
…
continue reading
Welcome to the Ennovation Podcast, where we bring you the latest trends, insights and expertise in life sciences and regulatory affairs.
…
continue reading
The Prospect Group is a leading global firm specializing in media, research, and consulting. We meet, and discuss the most relevant economic issues with, hundreds of the world’s leading business executives, political elites, and other influential personalities from a cross-section of industries and countries. Watch video interviews from and/or about Malaysia.
…
continue reading
This is Politics & Life Sciences (PLS) Radio which is an interplay of Life Sciences and Politics. I am your host Dean L. Fanelli, Ph.D. I am an Intellectual Property attorney in Washington, DC. My practice focuses on issues attendant to the Life Sciences industry. On PLS, we will explores cutting edge topics involving the Biotech and Pharma ecosystems and looks at political or governmental policy issues affecting the Biotech and Pharma industries. Each week, PLS will have amazing guests incl ...
…
continue reading
Are you working in healthcare market research or competitive intelligence or market intelligence? Do you often face information overload, from the pharma news portals, clinical trial registries, regulatory agencies, financial reports, investor releases, pharma summits, investment news, and financial summits etc.? It is hard to keep a track of all the forces (external and internal) that affects a product’s development and performance in the healthcare/ pharmaceutical market. We at RAS Life Sc ...
…
continue reading
Join Hercules Capital in conversations with today’s top CEOs, CFOs, and investors in venture and private equity-backed companies. Learn about their strategies for financing rapid growth and scaling their businesses, as well as their unique interests and life stories that have shaped their paths to success.
…
continue reading
1
Pharma and Biotech Daily: Your Quick Update on Industry News and Developments
1:03
1:03
Play later
Play later
Lists
Like
Liked
1:03
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has received approval for label expansion, potentially boosting its market performance. Tonix has also secured approval for a new fibromyalgia medication. Additionally, Novo has teamed up with …
…
continue reading
1
FDA Approves Updated COVID-19 Vaccines Amid Controversy: What You Need to Know
1:15
1:15
Play later
Play later
Lists
Like
Liked
1:15
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. is set to testify before the Senate Finance Committee on September 4. This comes after the removal of CDC Director Susan Monarez and the appointment of HHS Deputy Secretary Jim O'Ne…
…
continue reading
1
7. Exploring new possibilities in reproductive medicine
28:24
28:24
Play later
Play later
Lists
Like
Liked
28:24
ReproNovo demonstrated continued investor interest in the area of reproductive medicine by closing a $65 million Series A round earlier this year. In this episode, ReproNovo’s CEO and co-founder Jean Duvall joins your host, Cormac Sheridan, to discuss the company’s development strategy and how it put together the financing deal. ReproNovo is not a …
…
continue reading
1
Pharma and Biotech Daily: The Latest Updates in the World of Pharmaceuticals and Biotechnology
1:04
1:04
Play later
Play later
Lists
Like
Liked
1:04
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. CDC Director Monarez was fired after less than a month due to internal unrest over new COVID-19 vaccine policies. Novo Nordisk is investing over $500 million in RNA obesity treatments. The FDA has approved updated COVID-19…
…
continue reading
1
367: The ouster of CDC's director, biotech venture firm rankings
27:35
27:35
Play later
Play later
Lists
Like
Liked
27:35
We bring on Washington correspondent Chelsea Cirruzzo to explain the ouster of CDC Cirector Susan Monarez and the resignations of other top officials. We also chat about STAT's annual VC rankings report, as well as ongoing issues at a major drug manufacturing site that was owned by Catalent and now owned by Novo Nordisk.…
…
continue reading
1
Pharma and Biotech Daily: Cutting Through the Noise in the Ever-Evolving Industry
1:25
1:25
Play later
Play later
Lists
Like
Liked
1:25
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Regeneron's experimental drug for myasthenia gravis, cemdisiran, has shown promising results in a Phase III trial and the company is aiming to file for FDA approval by 2026. Pharmaceutical spending in China has reached reco…
…
continue reading
1
The Neuroscience of Weight Regulation with Courage Therapeutics’ Dr. Roger Cone
51:16
51:16
Play later
Play later
Lists
Like
Liked
51:16
In this episode of the Xtalks Life Science Podcast, Senior Life Science Journalist Ayesha Rashid speaks with Dr. Roger Cone, PhD, founder of Courage Therapeutics, professor at the University of Michigan, a member of the National Academy of Sciences and a leading authority on the neuroscience of weight regulation. Dr. Cone shares insights from over …
…
continue reading
1
Innovations and Opportunities in Pharma and Biotech: A Daily Update
0:46
0:46
Play later
Play later
Lists
Like
Liked
0:46
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly's new oral obesity drug is progressing towards FDA approval in 2025 after positive results from the second phase III trial for Orfoglipron. Analysts are optimistic about the potential for a "double-digit billion dolla…
…
continue reading
1
FDA’s program to speed up US manufacturing buildouts is short on detail
5:49
5:49
Play later
Play later
Lists
Like
Liked
5:49
While the agency’s PreCheck regulatory framework is a good first step, it remains to be seen whether the program boosts U.S. drug manufacturing, says former FDA official.Greg Slabodkin Read by Brittany Duncan https://www.pharmamanufacturing.com/all-articles/article/55309136/fdas-program-to-speed-up-us-manufacturing-buildouts-is-short-on-detail…
…
continue reading
1
Pharma and Biotech Daily: AbbVie Acquires Gilgamesh, IPO Stalemate Ends, Oral Obesity Therapies Disappoint
1:16
1:16
Play later
Play later
Lists
Like
Liked
1:16
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Gilgamesh Pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with Emraclidine in schizophrenia treatment. The biotech industr…
…
continue reading
1
Pharma and Biotech Daily: Your Daily Dose of What Matters
2:50
2:50
Play later
Play later
Lists
Like
Liked
2:50
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##New drug approval for rare genetic disorderToday, the FDA announced the approval of a new drug for a rare genetic disorder that affects approximately 1 in every 50,000 people. This drug has shown promising results in cl…
…
continue reading
After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry’s second-quarter performance. Among U.S. pharma heavyweigh…
…
continue reading
1
Pharma and Biotech Daily: RFK Jr. Accused of Spreading Mistrust, J&J Increases US Manufacturing, Fedegari Becomes One-Stop Solution Provider
0:55
0:55
Play later
Play later
Lists
Like
Liked
0:55
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. HHS employees have accused RFK Jr. of spreading public mistrust against the CDC after a shooting at their headquarters. They have asked him to stop spreading health misinformation, especially about vaccines and infectiou…
…
continue reading
1
366: Viking’s obesity flop, ‘pharma to table’ drug sales
24:28
24:28
Play later
Play later
Lists
Like
Liked
24:28
On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Therapeutics and the investor cult that embraces it, both of which performed a painful belly flop this week. Then, we’ll dish on the growing “pharm to tabl…
…
continue reading
1
Navigating the Complexities of Pharma and Biotech: A Daily Overview
1:34
1:34
Play later
Play later
Lists
Like
Liked
1:34
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA is pushing new guidelines for cancer trials, recommending overall survival as a primary endpoint. Capricor Therapeutics is asking the FDA to reconsider their rejection of a treatment for DMD cardiomyopathy with th…
…
continue reading
1
Pharma and Biotech Daily: Weight Loss Woes, Vaccine Strategies, and Industry Updates
1:09
1:09
Play later
Play later
Lists
Like
Liked
1:09
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Viking Therapeutics' oral obesity pill, VK2735, achieved over 12% weight loss in a clinical trial, causing their stock to plummet due to safety concerns. The pending approval of oral Wegovy has also brought attention t…
…
continue reading
1
New Jersey remains hot life sciences hub despite macroeconomic, funding headwinds
5:25
5:25
Play later
Play later
Lists
Like
Liked
5:25
The Garden State, called the “medicine chest” to the world, continues to show robust activity with life sciences firms accounting for nearly 30% of all Q2 leasing activity.Greg Slabodkin Read by Brittany Duncan https://www.pharmamanufacturing.com/all-articles/article/55308250/new-jersey-remains-hot-life-sciences-hub-despite-macroeconomic-funding-he…
…
continue reading
1
Exploring Immunomodulation Without Immunosuppression with Artax Biopharma’s Dr. Rob Armstrong
37:53
37:53
Play later
Play later
Lists
Like
Liked
37:53
In this episode of the Xtalks Life Science Podcast, host Ayesha Rashid speaks with Rob Armstrong, PhD, CEO of Artax Biopharma, a company pioneering a novel class of oral small molecule drugs known as Nck modulators to treat autoimmune diseases. Unlike traditional therapies that suppress the immune system, Artax’s approach aims to restore immune bal…
…
continue reading
1
Niche News Update: Returning Soon with Enhanced Coverage
1:40
1:40
Play later
Play later
Lists
Like
Liked
1:40
Niche News update on our upcoming relaunch with enhanced journalistic standards, better source verification, and daily coverage across multiple topics. We're returning soon with improved quality and uninterrupted service.By Niche News
…
continue reading
1
Pharma and Biotech Daily: Eli Lilly Raises Prices, RFK Jr. Supports mRNA Cancer Vaccines
0:53
0:53
Play later
Play later
Lists
Like
Liked
0:53
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly plans to raise drug prices in Europe in response to Trump's Most Favored Nation policy. RFK Jr. has expressed support for mRNA cancer vaccines after cutting mRNA BARDA contracts. Precigen wins FDA approval for an…
…
continue reading
1
The battle of the obesity drug heavyweights
26:17
26:17
Play later
Play later
Lists
Like
Liked
26:17
While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s GLP-1s quarter after quarter, this most recent earnings season delivered a few surprises. It’s a good moment to jump back in and assess where the two rivals stand in the market and where their pipelines are headed in the near te…
…
continue reading
1
Pharma and Biotech Daily: Eli Lilly's $1.3 Billion AI Investment, Schrodinger's Drug Discontinuation, and Trump's Tariff Delay
0:43
0:43
Play later
Play later
Lists
Like
Liked
0:43
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Eli Lilly has invested $1.3 billion in a partnership with Superluminal, an AI/ML startup focusing on endocrine and cardiometabolic diseases to develop new small molecule obesity medications. Schrodinger has discontinued t…
…
continue reading
1
365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
27:45
27:45
Play later
Play later
Lists
Like
Liked
27:45
We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to animal testing, and why they’re the subject of hot debate among scientists.By STAT
…
continue reading
1
Biotech Buzz: Safety data on Elevidys, Arrowhead's rise, and Novo Nordisk's fall
1:58
1:58
Play later
Play later
Lists
Like
Liked
1:58
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sarepta has released new safety data for their gene therapy Elevidys, showing zero ambulatory deaths in patients with Duchenne muscular dystrophy. This data confirms the therapy's positive risk/benefit profile. Meanwhile…
…
continue reading
1
Advancing Neurotherapeutics for Fragile X and Beyond with Spinogenix CMO Dr. Craig Erickson
37:11
37:11
Play later
Play later
Lists
Like
Liked
37:11
In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Craig Erickson, MD, chief medical officer at Spinogenix and a leading expert in translational neurodevelopmental research. Dr. Erickson shares insights into Spinogenix’s work on restoring synapses to reverse cognitive and motor decline in conditions like Fragile X Syndrome, ALS,…
…
continue reading
1
Pharma and Biotech Daily: Bayer's $1.3B Deal, Arrowhead's Stock Drop, Vaccine Study Standoff, and More
1:00
1:00
Play later
Play later
Lists
Like
Liked
1:00
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Bayer has secured a $1.3 billion deal with Kumquat Biosciences for exclusive access to their small-molecule KRAS G12D blocker. Meanwhile, Arrowhead has navigated through the Sarepta storm and experienced a drop in sto…
…
continue reading
FDA approves ketamine for surgical pain management as PharmaTher achieves historic milestone. Tonix Pharmaceuticals approaches critical fibromyalgia drug approval deadline.By Niche News
…
continue reading
1
Pharma and Biotech Daily: Stay Informed on the Latest Industry Updates
1:11
1:11
Play later
Play later
Lists
Like
Liked
1:11
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to his position as director of the Center for Biologics Evaluation and Research at the FDA after a sudden exit less than two weeks ago. The FDA has restricted the patient pool for bluebird's Skys…
…
continue reading
FDA grants accelerated approval for Jazz Pharmaceuticals' Modeyso, Biogen's Alzheimer's treatment awaits subcutaneous formulation decision, and RemeGen advances cancer therapy trials.By Niche News
…
continue reading
1
The Latest in Pharma and Biotech: Updates and Insights
1:36
1:36
Play later
Play later
Lists
Like
Liked
1:36
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to the FDA as the Chief of the Center for Biologics Evaluation and Research, just 10 days after his mysterious departure. His return comes after a short "vacation" in California, and it is believ…
…
continue reading
The FDA launches its PreCheck Program to speed up approvals, while the FTC moves to block Edwards Lifesciences' acquisition of JenaValve. Leadership changes at an FDA center may impact future timelines.By Niche News
…
continue reading
1
Is Trump’s MFN pricing order more bark than bite?
17:08
17:08
Play later
Play later
Lists
Like
Liked
17:08
Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored Nation drug pricing reforms in the U.S., analysts and industry watchers are questioning how far the president’s authority extends, while several drugmakers have signaled a willingness to negotiate. In this week’s episode of …
…
continue reading
1
Pharma and Biotech Daily: Navigating Challenges and Seizing Opportunities in the Industry
1:10
1:10
Play later
Play later
Lists
Like
Liked
1:10
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly is facing significant drug pricing pressure, with issues ranging from the pricing of their weight loss pill Orfoglipron to market battles with competitors like Novo Nordisk. Despite the challenges, Lilly's exec…
…
continue reading
1
364: Closing a zombie biotech, and Lilly's disappointing obesity readout
37:55
37:55
Play later
Play later
Lists
Like
Liked
37:55
We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and her advice for other biotech CEOs. We also chat about a disappointing readout from Eli Lilly's key small molecule GLP-1 candidate, setbacks in Vertex's…
…
continue reading
1
Pharma and Biotech Daily: Novo Nordisk's Focus on Obesity, Chinese Biotech Partnerships, and Policy Pressures in the Industry
2:05
2:05
Play later
Play later
Lists
Like
Liked
2:05
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk's new CEO, Maziar Mike Doustdar, is focusing on developing more drugs for obesity and diabetes while trimming the company's pipeline. The Department of Health and Human Services is terminating around $500 milli…
…
continue reading
1
Driving Neuro Innovation with Neurizon Therapeutics CEO Dr. Michael Thurn
44:15
44:15
Play later
Play later
Lists
Like
Liked
44:15
In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Michael Thurn, PhD, Managing Director & CEO, Neurizon Therapeutics, a company focused on advancing treatments for neurodegenerative diseases, including ALS, with expansion efforts in Alzheimer’s, Parkinson’s, Huntington’s and others. With over 25 years of experience in biotech i…
…
continue reading
1
Pharma and Biotech Daily: Your Quick Update on the Latest News in the Industry
2:28
2:28
Play later
Play later
Lists
Like
Liked
2:28
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Breaking News: Pfizer announces successful COVID-19 vaccine trialsIn a groundbreaking announcement, Pfizer revealed that their COVID-19 vaccine candidate has shown to be over 90% effective in preventing the virus. This …
…
continue reading
1
Pharma and Biotech Daily: Vaccine Rates Drop, Glioblastoma Research Soars, and FDA's Surprising Rejection
1:02
1:02
Play later
Play later
Lists
Like
Liked
1:02
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. BioNTech is focusing on infectious diseases as vaccine rates drop, with expectations that the US COVID-19 vaccination rate will decrease slightly. Glioblastoma research is seeing increased funding and interest from compa…
…
continue reading
1
Rebuilding trust: compassionate communication and public health (Sponsored)
39:40
39:40
Play later
Play later
Lists
Like
Liked
39:40
In the latest episode of Health Matters, vaccine expert Dr. Paul Offit joins host Wendy Lund to discuss the growing crisis of vaccine hesitancy and what can be done to rebuild trust. Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, points to the COVID-19 pandemic as a turning point, citing perceived government…
…
continue reading
1
Pharma and Biotech Daily: Moderna, Regeneron, and FDA Updates
1:02
1:02
Play later
Play later
Lists
Like
Liked
1:02
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna CEO Stephane Bancel has stated that the company is not interested in pursuing mergers and acquisitions, preferring to focus on research and development partnerships instead. Former President Trump has threatened 17 …
…
continue reading
1
Untangling Sarepta’s gene therapy fallout and a growing trust deficit
27:07
27:07
Play later
Play later
Lists
Like
Liked
27:07
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths. In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing paus…
…
continue reading
1
Top Highlights in Pharma and Biotech: Biogen's Leqembi Sales Surge, Moderna Cuts Workforce, AbbVie Celebrates Success
0:37
0:37
Play later
Play later
Lists
Like
Liked
0:37
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biogen's sales of the partnered Alzheimer's drug Leqembi have climbed 20% in the second quarter, while CEO Chris Viehbacher dismisses rumors of disagreements with Eisai. Moderna has cut 10% of its global workforce as par…
…
continue reading
1
363: What Vinay Prasad’s ouster means for biotech and the FDA
44:23
44:23
Play later
Play later
Lists
Like
Liked
44:23
This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s biologics division. This surprising development came after a series of controversial decisions he made on Sarepta’s gene therapy for Duchenne muscular dystrophy and a barrage of political attacks from co…
…
continue reading
1
The Biotech Buzz: Latest News and Updates in Pharma and Biotech World
1:58
1:58
Play later
Play later
Lists
Like
Liked
1:58
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the …
…
continue reading
1
Restoring Synapses to Fight ALS, Alzheimer’s and More with Spinogenix CEO Dr. Stella Sarraf
38:49
38:49
Play later
Play later
Lists
Like
Liked
38:49
In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Stella Sarraf, PhD, founder, CEO and director of Spinogenix, a company pioneering neurodegenerative therapeutics designed to restore synapses with the potential to reverse cognitive and motor decline in conditions such as ALS, Alzheimer’s disease, schizophrenia and other neurolo…
…
continue reading
